Hong Kong Respiratory Medicine

Luis Paz-Areshe TLancet Oncology, Early Online Publication, 24 January 2012 doi:10.1016/S1470-2045(12)70001-3

The EGFR signalling pathway is relevant in many tumour types and is a successful exploitable target for anticancer treatment, including for non-small-cell lung cancer (NSCLC). Erlotinib, a tyrosine kinase inhibitor (TKI), has shown efficacy, although of limited magnitude, compared with placebo in unselected patients with NSCLC in the second-line or third-line settings. 1 The discovery of EGFR-activating mutations in NSCLC and their implications in the biology of the underlying disease, including s ...

Weblink here